A Nationwide Real-world Evaluation of Upfront Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma in the Immunotherapy Era
In the absence of randomised controlled trials (RCTs), our results indicate a preference for uCN in patients with mRCC with favourable prognostic factors in the IO era. Owing to the risk of residual confounding, strong evidence from RCTs is needed.
Authors
- Adriaan D. Bins
- Katja K.H. Aben (ORCID: https://orcid.org/0000-0002-0214-2147)
- Maarten J. Bijlsma (ORCID: https://orcid.org/0000-0002-7330-6006)
- Hilin Yildirim (ORCID: https://orcid.org/0000-0003-0965-7968)
- Arnoud W. Postema (ORCID: https://orcid.org/0000-0003-0629-871X)
- Axel Bex (ORCID: https://orcid.org/0000-0002-8499-2662)
- Maureen J.B. Aarts (ORCID: https://orcid.org/0000-0002-6381-1500)
- Patricia Zondervan (ORCID: https://orcid.org/0000-0003-0812-078X)
- Martijn G.H. van Oijen (ORCID: https://orcid.org/0000-0001-7897-1710)
Institutions
- Radboud University Nijmegen (NL)
- Royal Free London NHS Foundation Trust (GB)
- University of Groningen (NL)
- Leiden University Medical Center (NL)
- Maastricht University Medical Centre (NL)
- Radboud University Medical Center (NL)
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
- Netherlands Comprehensive Cancer Organisation (NL)
- Amsterdam University Medical Centers (NL)
- University College London (GB)
- University of Amsterdam (NL)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2025-04-12
- DOI
- https://doi.org/10.1016/j.euo.2025.02.011
- Citations
- 7
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 10.63
Funders
- Strong